United & United’s Post

Featured in the IP Knowledge Hub 💡 Innovation and genetic resource access are balanced in biotechnology and intellectual property. The field of biotechnology has experienced explosive growth in recent years. This dynamic discipline sits at the crossroads of biology and technology, offering various applications designed to improve human life and the environment... Read the full article here 👉 https://lnkd.in/e7m6VC97 Written by Rashmita Das, Content Strategist, United & United. Want to feature your own article in the IP Knowledge Hub? Contact chris@ctclegalmedia.com today! #patent #lawyer #IPknowledgehub #IPlaw #innovation #geneticresourceaccess #biotechnology #humanlife #environment

Over the past few years, biotechnology has become one of the most promising sectors of the economy.  However, it combines growth potential and high risk, so companies in this industry depend on investors greatly. Today all biotechnologies are divided into two large groups: classical and modern [1]The first group is based on classical methods such as crossing and fermentation to produce and modify existing products using living microorganisms.  The group of modern biotechnologies relies on genetic engineering methods, such as manipulating genes, cells, and tissues and altering DNA. It is customary to separate biotechnologies using a color system: red - medicine, whiteindustry, green - agriculture, blue-development using marine organisms, gray environmental protection 121. The global biotechnology market is estimated at $ 752.88 billion in 2020 and is expected to grow at a CAGR of 15.83% from 2021 to 2028 [3].  The growth is mainly due to restructuring by companies of their operations and recovery from CoviD-19, which previously led to restrictive containment measures, including social distancing, distant working, and the closure of commercial activities, which led to operational problems.  Also, the market's growth might be explained by favorable government initiatives aimed at developing the biotechnological sector worldwide.  In addition, government initiatives are focused on modernizing the drug regulatory system, standardizing clinical trials, improving cost recovery policies, and accelerating the product approval process, which provides the market with opportunities for rapid growth. The German biotech market is one of the largest not only in Europe but worldwide.  The volume of biotechnology products is growing every year in correlation with the level ofl innovation in the country.

Biotechnology is a dynamic field that requires careful planning, along with ethical and safety guidelines, to pave the way for the development of new medicines, scientific breakthroughs, and much more. However, navigating through this realm poses many challenges. It demands vigilance about the latest guidelines by the relevant authorities while simultaneously carving out a path that proves beneficial in the long run. To learn more about the challenges encountered in the realm of biotechnology and potential solutions, read our informative article on the topic: From Lab to Market: Navigating the Challenges of Biotech Commercialization. https://lnkd.in/d_cb4bbD #TCG #TCGIBP #BiotechResearch #BiotechPark

🔬 𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗣𝗮𝘁𝗲𝗻𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗼𝗳 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗠𝗮𝘁𝗲𝗿𝗶𝗮𝗹𝘀 🌱 In the rapidly advancing world of biotechnology, the patentability of biological materials—such as genes, proteins, microorganisms, and plant varieties—has become a topic of significant importance. Patents for these materials can propel research, attract investments, and foster innovation, but the path to securing them can be complex. 𝗞𝗲𝘆 𝗣𝗼𝗶𝗻𝘁𝘀 𝗼𝗻 𝗣𝗮𝘁𝗲𝗻𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗶𝗻 𝗕𝗶𝗼𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆: 🔹 𝗡𝗼𝘃𝗲𝗹𝘁𝘆 & 𝗨𝘁𝗶𝗹𝗶𝘁𝘆: For biological materials to be patentable, they must be novel, non-obvious, and useful. This ensures that only genuinely innovative advancements are protected. 🔹 𝗛𝘂𝗺𝗮𝗻-𝗠𝗮𝗱𝗲 𝘃𝘀. 𝗡𝗮𝘁𝘂𝗿𝗮𝗹𝗹𝘆 𝗢𝗰𝗰𝘂𝗿𝗿𝗶𝗻𝗴: Naturally occurring biological substances (e.g., DNA sequences) are generally not patentable. However, if they are isolated, modified, or synthetically produced, they can be patented if they meet specific criteria. 🔹 𝗘𝘁𝗵𝗶𝗰𝗮𝗹 𝗮𝗻𝗱 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀: The patenting of biological materials often raises ethical and environmental questions, and patents may be subject to regulatory scrutiny to ensure compliance with local and international guidelines. 🔹 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗳𝗼𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀: Patenting biological materials can provide a competitive advantage for research institutions and biotech companies, attracting funding and facilitating commercialization. At ThinkNew, we specialize in navigating the complexities of patenting biological innovations. Whether you’re working on genetically modified organisms, biotechnological processes, or novel bio-compounds, we’re here to help secure your IP rights. 🌐 Ready to patent your biotech innovation? Reach out to us at www.thinknew.in or connect with us here https://wa.me/9956535431 to learn more! #Biotechnology #Patents #IPR #Innovation #BiologicalMaterials #Research #ThinkNew #PatentStrategy #BiotechInnovation #IntellectualProperty #ResearchImpact

Recent analysis reveals the dynamic landscape of biotech innovation globally, highlighting a significant presence in industrial and medical applications. The US leads with 39% of biotech patents, followed by the EU at 18%, and China's rapidly growing 10% share. This study underscores the strategic directions for enhancing the EU's competitiveness in biotech, aiming to overcome challenges and leverage opportunities in agriculture, industry, and medicine.

on march 20th, EU commission announcedkey decisions to support more research and development, complex administrative procedures threatening #Europe’s competition, the difficulty in accessing finance, skills, intellectual property, as well as value chain obstacles and gaining #public acceptance Their list of actions to tackle those issues includes stimulating more research and development, including helping companies make better use of #AI, as well as stimulating market demand, shortening the time it takes to place innovations on the market, and channelling more investments into #biotech. Commenting on the proposal, Claire Skentelbery, director general of EuropaBio - the European Association for Bioindustries, called for immediate implementation of the actions. “The next Commission must combine long-term vision and bold ambitions with immediate and urgent attention to resolve existing barriers to growth. The world is accelerating industrial outputs from biotechnology, and we need to move with it,” Claire Skentelbery added.

Peter Lee, Ph.D., Microsoft Research, will address how new advances in technologies like #AI and #machinelearning are transforming #biotechnology in the closing plenary of our National Biotechnology Conference on May 16. Join us at #NBC2024!